BCS Private Wealth Management Inc. Takes $1.28 Million Position in Eli Lilly and Company $LLY

BCS Private Wealth Management Inc. bought a new position in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,638 shares of the company’s stock, valued at approximately $1,277,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter worth about $27,000. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $31,000. Bare Financial Services Inc raised its stake in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the last quarter. Finally, Blume Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 1.6%

Shares of Eli Lilly and Company stock opened at $981.89 on Wednesday. The business has a fifty day simple moving average of $928.62 and a 200 day simple moving average of $814.21. The stock has a market cap of $928.26 billion, a PE ratio of 48.04, a price-to-earnings-growth ratio of 1.11 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Morgan Stanley upped their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, Scotiabank started coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,091.62.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.